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Abstract
Background: Tissue factor pathway inhibitor-2 (TFPI-2) is an extracellular matrix associated broad-spectrum Kunitz-
type serine proteinase inhibitor. Recently, down regulation of TFPI-2 was suggested to be involved in tumor
invasion and metastasis in some cancers.
Methods: This study involved 12 normal cervical squamous epithelia, 48 cervical intraepithelial neoplasia (CIN), and
68 cervical cancer. The expression of TFPI-2, Ki-67 and vascular endothelial growth factor (VEGF) were investigated
by immunohistochemistry staining. The apoptolic index(AI) was determined with an in situ end-labeling assay
(TUNEL). And the marker of CD34 staining was used as an indicator of microvessel density (MVD).
Results: TFPI-2 expression has a decreasing trend with the progression of cervical cancer and was significantly
correlated with FIGO stage, lymph node metastasis and HPV infection. In addition, there were significant positive
correlations between the grading of TFPI-2 expression and AI(P = 0.004). In contrast, the expression of TFPI-2 and
VEGF or MVD was negatively correlated (both p < 0.001). However, we did not establish any signiﬁcant correlation
between Ki-67 and TFPI-2 expression in cervical cancer.
Conclusions: The results suggested that the expression of TFPI-2 had a decreasing trend with tumor progression
of cervical cancer. There was a close association between the expression of TFPI-2 and tumor cell apoptosis and
angiogenesis in patients with cervical cancer. TFPI-2 may play an inhibitive role during the development of cervical
cancer.
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Background
Cervical cancer is the second most common malignancy
in women around the world [1]. Cervical cancer occurs
in a multi-step process, a sequential transition from a
cervix with a normal epithelium to cervical intraepithe-
lial neoplasia (CIN) and invasive cervical cancer. It is
clear that persistent high-risk Human Papillomavirus
(hr-HPV) infections are the strongest epidemiologic risk
factor for the development of invasive cervical cancer
[2]. However, HPV infection alone is not sufﬁcient to
cause cervical cancer. Consequently, much interest has
been focused on the molecular basis which contribute
to drive the progression of cervical cancer. Proteolytic
degradation of the extracellular matrix (ECM) is consid-
ered to be an essential step in tumor growth and metas-
tasis. Tissue factor pathway inhibitor-2 (TFPI-2), a 32-
kDa broad-spectrum Kunitz-type serine proteinase inhi-
bitor, abundantly produced by a variety of human tis-
sues and directionally secreted into their ECM [3-5].
TFPI-2 is thought to negatively regulate the enzymatic
activity of ECM-associated trypsin, plasmin, and VIIa-
tissue factor complexly to protect the ECM stability [6].
In humans, TFPI-2 gene is located on chromosome
7q22, and consists of three Kunitz-type serine proteinase
inhibitory domains similar to the classical tissue factor
pathway inhibitor (TFPI-1). While the first Kunitz-type
domain of TFPI-2 appears to contain the main
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nases [7]. The degradation of ECM involves a variety of
proteases, particularly metalloproteinases (MMPs).
MMPs take part in virtually all events of ECM remodel-
ing. It is reported that upregulation the expression of
MMPs strongly associated with the progression of sev-
eral malignancies, including cervical cancer [8]. TFPI-2
has also been reported to effectively regulate MMPs
activity by inhibiting activation of proMMPs by trypsin-
like serine proteinases [9]. TFPI-2 gene promote con-
tains a complete CpG island region of at least 220-bp. It
is observed that the TFPI-2 expression, decreasing or
even diminishing, attributed to promoting hypermethy-
lation in nasopharyngeal carcinoma [10]. Recent ﬁndings
suggest decreasing TFPI-2 expression plays a significant
role in inhibiting cell migration and tumor invasion by a
mechanism that involves its inhibitory activity [11,12].
In addition, it is revealed that aberrant methylation of
TFPI-2 was present in a high proportion of cervical can-
cer clinical samples and cell lines [13,14]. Thus, TFPI-2
might be a target gene in cervical cancer. However, the
expression of TFPI-2 has not yet been examined in cer-
vical tissues.
In this study, we investigated TFPI-2 expression in
cervical lesions by immunohistochemical staining. We
then studied the correlation between TFPI-2 and apop-
tosis, ki-67, VEGF and MVD expression to evaluate
whether TFPI-2 contributed to tumor cell apoptosis,
proliferation and angiogenesis in patients with cervical
cancer.
Materials and methods
Specimens
A total of 128 uterine cervical samples was collected
from patients who had undergone surgery at Shengjing
Hospital (Shenyang City, Liaoning Province, PR.China)
between 2009 and 2010. The specimens included 48 cer-
vical intraepithelial neoplasia (CIN) and 68 invasive cer-
vical cancer(ICC), along with 12 normal squamous
epithelial specimens. The median age of all the patients
was 43 years (range 22-71 years). The normal squamous
epithelial specimens were collected from uteri of
patients who had undergone hysterectomy without
malignancy. Ths study was approved by the Ethics Com-
mittee of China Medical University University. Informed
written consent was obtained from all subjects prior to
the study.
The histopathological diagnosis was based on World
Health Organization classifications, and the clinical sta-
ging was defined according to the International Federa-
tion of Gynecology and Obstetrics (FIGO) clinical
staging system. All the subjects had complete clinical
and pathological data, and none received preoperative
radiotherapy, chemotherapy and biological therapy
before surgery.
Immunohistochemical staining(IHC)
T h es p e c i f i ca n t i b o d i e sa g a inst TFPI-2 was purchased
from Biosynthesis Biotechnology co. (Peking, China), Ki-
67, VEGF, and CD34 were purchased from Zhongshan
Goldenbridge Biotechnology co.(Peking, China).
Surgically resected tissue samples were routinely fixed
in 10% formalin solution, paraffin-embedded, and cut
into 4-μm-thick sections. After deparaffinization and
rehydration, the sections were heated in three 5-minute
periods in microwave oven at 100°C with sodium citrate
buffer (10 mM; pH 6), cooled down in the same buffer
at room temperature, and subsequently incubated 20
min with 3% hydrogen peroxide. The antibodies for
TFPI-2, Ki-67, VEGF and CD34 were used at 1:200,
1:100, 1:100 and 1:100, respectively. The serial sections
were incubated with primary antibodies in a humid
chamber at 4°C overnight. Sections were washed three
times in phosphate-buffer solution (PBS) and further
incubated with a biotinylated secondary antibody for 30
min at room temperature. Streptavidin-horseradish per-
oxidase conjugate was added and the peroxidase activity
was made visible with diaminobenzidine and counter-
stained with hematoxylin for 30 sec. As a control experi-
ment, we performed an identical immunohistochemical
procedure with omission of the primary antibody.
TUNEL assay
Apoptosis of tumor sections was detected by TUNEL
assay using the In Situ Cell Death Detection Kit, POD
which was purchased from Roche (Mannheim, Ger-
many). According to the manufacturer’s instructions,
after routine deparaffinisation, sections were digested
with proteinase K working solution at room temperature
for 15 minutes and washed twice with PBS. TUNEL
reaction mixture was prepared. The sections were incu-
bated with 50 μl TUNEL reaction mixture each for 60
min at 37°C in a humidified atmosphere in the dark.
Sections were rinsed 3 times with PBS and further incu-
bated with Converter-POD in a humidified chamber for
30 min at 37°C. After the sections were washed with
PBS for 3 times, DAB was used as chromogen and sec-
tions were counterstained with Hematoxylin.
HPV testing
The cervical swab samples were collected and trans-
ported using the PreservCytR LBC medium (Cytyc, Bed-
f o r d ,M A ,U S A ) .S a m p l e sm a yb eh e l du pa ta
temperature between 2°C and 8°C and shipped to the
testing laboratory, a preservative has been added to the
Transport Medium to retard bacterial growth and to
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ried out by the Virus Laboratory, Shengjing Hospital
(Shenyang City, Liaoning Province, PR.China) using the
HPV GenoArray test kit (HybriBio, Hong Kong) accord-
ing to the manufacturer’s instructions. The GenoArray
test is capable of amplifying 21 HPV genotypes: 13 HR
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and
68), 5 LR genotypes (6, 11, 42, 43, and 44), and 3 types
common in China (53, 66, and CP8304).
Grading of immunostaining
Afterwards, the results of immunostaining were
mounted and examined using a bright-field microscope
by two independent observers without knowledge of the
clinical data for each patient.
For assessing the immunostaining, we used a semi-
quantitative approach to grade the TFPI-2 protein
staining intensity as follows. The strongest staining was
set at 100% and the staining intensity was rated as fol-
lows: 75% to 100% (++++), 50% to75% (+++), 10 to
50% (++), and < 10% (+) (Figure 1). The VEGF expres-
sion in the tumor cells was also evaluated using a
semi-quantitative scoring system: 0 for absence of
immunostaining(-), 1 for light staining(+), 2 for moder-
ate staining(++), and 3 for heavy staining(+++). All
TUNEL signal positive or Ki-67 immunolabelling
nuclei were then counted from the total number of at
least 2000 tumor cells in randomly selected fields in
each case. In CIN lesions, these counting procedures
were performed in the whole epithelial layers. The
apoptotic cell index (AI) and Ki-67 labeling index (PI)
were calculated as number per 100 cells. Microvessel
density (MVD) was determined by counting the num-
ber of vessels plus immunoreactive endothelial cells
per 200× high power field in the area of the most
intense vascularization (hot spot) of each tumor, and
the average count was recorded.
Statistical analysis
Statistical analysis was performed using the SPSS 17.0
program package. Mean values were compared with
unpaired Student’s t-test or one-way ANOVA analysis,
and categorical variables were compared with Fisher’s
Exact Test. The Chi-square linear trend test was used to
check for correlation between TFPI-2 positive expres-
sion and clinicopathologic factors. The Spearman’sc o r -
relation test was used to analyze consistency level
between TFPI-2 and AI, PI, VEGF or MVD. The Krus-
kal-Wallis H test was used to analyze the association
between the intensity of TFPI-2 immunoexpression and
HPV infection. For the sake of statistical convenience,
the positive results of -, +, ++, +++ and ++++ were
scored as 0, 1, 2, 3 and 4. Two sided P-values less than
0.05 were considered statistically significant.
Figure 1 The grading of immunohistochemical staining for TFPI-2. Immunohistochemical staining of cervical tissues for TFPI-2 (A-E). The
immunostaining intensity was deﬁned as grade 0 (no detectable staining, A), grade1 (weak staining, B), grade 2(clear but not so strong staining,
C), grade 3 (more strong staining, D) and grade 4 (stronggest staining, E). The nuclei were counterstained with hematoxylin blue. Image
magnifications are 200×.
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Patient characteristics
Immunohistochemical analysis was performed on 128
pathological cervical neoplasms, including 48 CIN and
68 ICC, and along with 12 normal squamous epithelial
specimens. Patient characteristics were presented in
Table 1.
Expression of TFPI-2 in cervical neoplasms
We observed TFPI-2 was expressed only in the cyto-
plasm of the cervical tissues. All normal squamous
epithelial cells showed potent immunostaining for cyto-
plasmic TFPI-2 (Figure 2A), while the staining for cyto-
plasmic TFPI-2 was lower in ICC (Figure 2D). In CIN,
the immunostaining of cytoplasmic TFPI-2 was clear
but not so strongly observed. Cytoplasmic TFPI-2
immunostaining in CIN I was potent (Figure 2B), while
that in CIN II and III was weak (Figure 2C). Clearly, the
immunostaining of TFPI-2 decreased together with
tumor progression, this being statistically significant (p
< 0.005).
Cells undergoing apoptosis is a form of programmed
cell death characterized leading to apoptotic bodies.
TUNEL signals were detected not only in these cells but
also in morphologically viable cells at the start of
apoptosis, as identified by distinct nuclear staining(Fig-
ure 2F). Ki-67 staining was expressed in the nuclei of
the cervical tissues(Figure 2E). Immunohistochemical
staining of VEGF is mainly distributed in the cytoplasm
of epithelial cells of the cervix(Figure 2G). The immu-
noreactivity of anti-CD34 antibody was located only on
the cytoplasm of endothelial cells, and not on tumor
cells or interstitial cells(Figure 2H).
Correlation between clinicopathologic factors and TFPI-2
expression
Data on the correlation between clinicopathologic fac-
tors and the grading of TFPI-2 expression are summar-
ized in Table 2. Grading of expression of TFPI-2 was
significantly associated with histopathological, FIGO
stage, lymph node metastasis and HPV infection.
The proportion of grading expression of TFPI-2 have
a decreasing trend from normal, CIN to ICC, indicating
that the expression of TFPI-2 have an association and
linear relationship with the increase of malignant poten-
tial of cervical neoplasia. The expression of TFPI-2 in
CIN II and III was significantly lower than that in CIN
I, indicating that the decreased TFPI-2 expression may
link to the increase of malignant potential of CIN. But
the decreasing trend of grading proportion was not
observed.
Further, we analyzed there was no significant differ-
ence between the expression of TFPI-2 and differentia-
tion or histology. In contrast, the grading expression of
TFPI-2 was significantly having a decreasing trend with
FIGO stage, lymph node metastasis and HPV infection.
Thus, further examinations were done to analyze more
precisely the level of TFPI-2 in HPV infection by using
Kruskal-Wallis H Test. The proportion of TFPI-2
expression variations between HPV infected and non-
infected cases revealed that TFPI-2 expression in the
HPV positive samples was significantly lower compared
to HPV negative samples. Further, we divided the
patients with HPV infected into four groups, as Normal,
CIN I, CIN II/III and ICC. The relationship between
TFPI-2 expression and these HPV positive samples in
these four groups was significant (p < 0.001).(Table 3)
Correlation between TFPI-2 and apoptosis, ki-67, VEGF
and MVD expression
The analysis was done to clarify whether there is differ-
ence of AI, PI, VEGF and MVD according to TFPI-2
positive and negative samples. As shown in Table 4,
TFPI-2 negative AI in ICC is lower than the expression
of TFPI-2 positive ICC. The VEGF and MVD in the
TFPI-2 positive samples was significantly lower com-
pared to TFPI-2 negative samples in ICC. However,
there was no signiﬁcant correlation of PI between TFPI-
2 positive and negative samples.
Table 1 Clinical and pathological characteristics
Characteristics Number of cases (%)
Range 22-71(years)
Average 43 (years)
Samples
normal squamous epithelial specimens 12 (9.4)
cervical intraepithelial neoplasms (CIN) 48(37.5)
CIN I 21 (43.7)
CIN II/III 27(56.3)
invasive CC(ICC) 68(53.1)
well-differentiated(WICC) 13(19.1)
moderately differentiated(MICC) 39(57.4)
poorly differentiated(PICC) 16(23.5)
Histology
Squamous cell carcinoma(SCC) 61(89.7)
Adenosquamous cell carcinoma(ACC) 7(10.3)
Figo stage
Ia 9(13.2)
Ib 28(41.2)
IIa 21(30.9)
IIb 10(14.7)
Lymph nodes metastasis(LN)
Absent 51(75)
Present 17(25)
HPV infection
Absent 38(29.7)
Present 90(70.3)
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Page 4 of 9Figure 2 Immunohistochemical staining of TFPI-2, and Ki-67, TUNEL, VEGF and CD34 in cervical tissues. Immunohistochemical staining
of TFPI-2 in cervical tissues (A-D), and Ki-67 (E), TUNEL (F), VEGF (G) and CD34 (H) in ICC. The analysis showed TFPI-2 expression in normal
squamous epithelial cells showed strongly positive staining for cytoplasmic(A), clear cytoplasmic staining in CIN I (B), while CIN II and III show
potent staining (C), weak staining in tumor cells (D). The nuclei were counterstained with hematoxylin blue. Image magnifications are 200×.
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precisely the level of AI, LI, VEGF and MVD in normal
epithelial specimens, CIN, and ICC of TFPI-2 positive
samples. The AI clearly increased together with tumor
progression in the TFPI-2 positive samples, this being
statistically significant. The PI in CIN II and III and ICC
were signiﬁcantly higher than those in normal epithe-
lium. There was however no signiﬁcant difference
between CIN I and normal epithelium. The VEGF in
ICC were also signiﬁcantly higher than CIN and normal
epithelia, and there was no difference between CIN and
normal epithelium. The MVD was similar to VEGF.
Then, in order to analyze the consistency level
between the grading of TFPI-2 expression and AI, PI,
VEGF or MVD, 68 ICC samples were classified as -, +,
++ and +++ four groups. Spearman rank correlation test
was used. The data on the correlation are summarized
in Table 5. As a result, there were significant positive
correlations between the grading of TFPI-2 expression
and AI. In contrast, the expression of TFPI-2 and VEGF
or MVD was negatively correlated. But to PI, this trend
of statistical significance was not observed.
Discussion
H u m a nT F P I - 2 ,a l s ok n o w na sp l a c e n t a lp r o t e i n( P P 5 )
and matrix-associated serine protease inhibitor (MSPI),
is an ECM-associated Kunitz-type serine proteinase inhi-
bitor [15]. TFPI-2 plays an important role in normal
ECM remodeling, and is also becoming increasingly
recognized as a tumor suppressor gene. In several types
of malignancies, such as choriocarcinoma [16], glioma
[17], prostate cancer [18], pancreatic carcinoma [19] and
lung cancer [20], TFPI-2 has significantly demonstrated
tumor-suppressive functions during tumor cell invasion,
metastasis, apoptosis, proliferation and angiogenesis. It
was reported that, TFPI-2 showed high frequency of
CpG islands aberrantly methylated in both cervical can-
cer specimens and cell lines [13,14]. But, to our knowl-
edge, little is known on the role of TFPI-2 silencing in
cervical cancer. To investigate the relationship between
TFPI-2 and tumor cell apoptosis, proliferation and
angiogenesis in patients with cervical cancer, we ana-
lyzed the immunohistochemical expression levels of
TFPI-2, with relationship to AI, PI, VEGF and MVD in
cervical biopsy tissues. Our data suggested that TFPI-2
inhibited tumor apoptosis and metastasis of cervical
cancer and might be a regulatory molecule in the malig-
nant potential of cervical cancer.
In the present study, we found that TFPI-2 expression
in all patients with normal epithelial cells and CIN was
positive, while that was activated in 66.2% of cervical
carcinomas in immunohistochemical analysis. Our data
demonstrated that the grading expression of TFPI-2 had
a decreasing trend with the increase of malignant poten-
tial of cervical neoplasia. Similarly, immunoexpression of
TFPI-2 has been studied in many other different tumors
(laryngeal, breast, gastric, colon, pancreatic, renal, endo-
metrial cancer and glial neoplasms) and the expression
of TFPI-2 diminished with an increasing degree of
malignancy [21]. Wong et al analyzed the mRNA
expression of TFPI-2, their data suggested that when
compared with the corresponding nontumorous livers,
TFPI-2 was significantly under-expressed in approxi-
mately 90% of primary hepatocellular carcinomas [11].
It has also been reported that there was a good correla-
tion between the immunoexpression of TFPI-2 staining
score and mRNA levels measured by real-time PCR
[11,22]. Thus, the expression of TFPI-2 was decreased
in some tumors, which was consistent with the results
of our study. The mechanism of downregulation
of TFPI-2 expression during tumor progression was
signiﬁcantly correlated with the promoter aberrant
Table 2 Correlation between clinicopathologic factors
and TFPI-2 expression
Characteristics n TFPI-2 P
- + ++ +++ ++++
normal 12 0 0 0 2 10 < 0.001
CIN 48 0 3 19 18 8
CIN I 21 0 0 3 10 8 < 0.001
CIN II/III 27 0 3 16 8 0
ICC 68 23 25 19 1 0
WICC 13 2 5 6 0 0 0.474
MICC 39 13 15 10 1 0
PICC 16 8 5 3 0 0
Histology
SCC 61 19 22 19 1 0 0.304
ACC 7 4 3 0 0 0
Figo stage
I 37 5 17 13 1 0 0.003
II 31 18 8 6 0 0
LN metastasis
Absent 51 13 19 18 1 0 0.037
Present 17 10 6 1 0 0
HPV status
Absent 38 1 6 9 9 13 < 0.001
Present 90 26 22 25 12 5
Table 3 Association between HPV infection and TFPI-2
expression in normal and neoplastic cervical epithelium
n HPV-positive TFPI-2
- + ++ +++ ++++
Normal 12 3 0 0 2 2 1
CIN I 21 11 0 0 1 6 4
CIN II/III 27 18 0 2 12 4 0
ICC 68 58 22 20 16 0 0
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of TFPI-2 expression was signiﬁcantly correlated with
the promoter hypermethylation in some cancer lesions
and cell lines, such as nasopharyngeal carcinoma [10],
hepatocellular carcinoma [11], lung cancer [22] and
breast cancer [23].
We further analyzed the correlation of TFPI-2 expres-
sion and clinicopathologic factors of patients, to investi-
gate whether the expression of TFPI-2 could predict
increased risk of metastasis and malignancy. Our data
indicated that the grading of TFPI-2 gene expression
had a decreasing trend with FIGO stages, lymph node
metastasis and HPV infection of cervical cancer. Our
results were similar to the study of non-small-cell lung
cancer, in which the downregulation of TFPI-2 mRNA
was more frequently associated with advanced stages. It
was observed in stage I-II NSCLC (11/33, 33%) and
stage III-IV(11/26, 42%)[22].
There is no doubt that HPV infection is the most
important risk factor for the development of cervical
cancer [24]. But progression of an HPV-infected cervical
intraepithelial neoplastic to invasive cervical cancer is
infrequent. There are some other factors that influence
the susceptibility of HPV infection and drive progression
of HPV-induced neoplastic to invasive cervical cancer
[25]. Alessandro et al reported that the expression of
TFPI-2 downregulation in HPV16 and HPV18-infected
stage IB-IIA cervical cancers compared to normal cervi-
cal keratinocyte cultures [14]. We also observed that the
grading of TFPI-2 expression in the HPV positive
samples was significantly lower compared to HPV nega-
tive samples. Thus, TFPI-2 expression in cervical lesions
maybe correlates with the HPV activity.
These results suggest that the transcriptional repres-
sion of human TFPI-2 may have an important role dur-
ing the genesis or progression of cervical carcinoma. It
becomes of importance to clarify the role of TFPI-2
expression in cervix epithelial cells.
In the current study, we found that the AI clearly
increased together with tumor progression. In fact, loss
of AI has been suggested to be involved in malignant
transformation [26]. In addition, the data showed that
apoptosis was associated with TFPI-2 in cervical carci-
noma. The expression of TFPI-2- negative AI was lower
than TFPI-2 positive. We also found that there were sig-
nificant positive correlations between the grading of
TFPI-2 expression and AI by Spearman’s correlation
test. These data suggested that the diminish expression
of TFPI-2 in cervical cancer is associated with a
decrease in apoptosis. George et al reported that
restoration of TFPI-2 in U-251, a highly invasive human
glioblastoma cell line, activated both intrinsic and
extrinsic caspase-mediated, pro-apoptotic signaling path-
ways and induced apoptosis in these cells [27]. Further,
Prakasha et al reported that both TFPI-2 and R24K
KD1, whose mutated ﬁrst Kunitz-type domain, activated
the signaling pathways resulting in apoptosis, and their
data suggested that TFPI-2’s serine proteinase inhibitory
activity may play a role in this process [28]. Thus, the
findings suggested that TFPI-2 play an important role
with apoptosis in cervical carcinoma.
It is clear that VEGF dominantly expresses via a para-
crine pathway to surrounding microvessels in tumor
cells, and VEGF expression is critical for microvessel
density in malignancy [29]. In the current study, the
expression of TFPI-2 and VEGF was negatively corre-
lated. Therefore, we believe that decreased TFPI-2
expression correlates with increased expression of VEGF
in cervical carcinoma, suggesting that active TFPI-2
plays a suppressive role on VEGF gene expression.
Hitendra et al stably transfected HT-1080 ﬁbrosarcoma
Table 4 Correlation between TFPI-2 status and and AI, PI, VEGF and MVD during malignant grading
AI PI VEGF MVD(mean ± SD)
TFPI-2
(+)
TFPI-2
(-)
TFPI-2
(+)
TFPI-2
(-)
TFPI-2
(+)
TFPI-2
(-)
TFPI-2
(+)
TFPI-2
(-)
Normal 0a - 11.3a - 0.25a - 30.5 ± 12.5a -
CIN I 0.12a, b - 20.1a, b - 0.38a, b - 36.1 ± 7.9a, b -
CIN II/III 1.13a, c - 50.8c, d - 0.59a, b - 42.6 ± 24.3a, b -
ICC 2.41 1.8 57.5 64.7 1.2 2.2 63.5 ± 19.3 69.8 ± 21.0
P* 0.001 0.054 < 0.001 0.033
ap < 0.001 when compared to ICC; bp > 0.05 when compared to normal cervix;and cP < 0.001 when CIN I compared to CIN II/III; dP = 0.005 when CIN II/III
compared to ICC; P* when TFPI-2-negative compared to TFPI-2-positive. The TFPI-2 positive results of +,++,+++ and ++++ were merged into one group.
Table 5 Correlation between the grading expression of
TFPI-2 and AI, PI, VEGF and MVD in ICC
TFPI-2 n AI PI VEGF MVD(mean ± SD)
- 23 1.8 64.7 2.2 69.8 ± 21.0
+ 25 2.2 58.9 1.5 64.8 ± 19.2
++ 19 2.5 56.6 0.8 62.3 ± 18.2
+++ 1 4.8 39 0 54.4 ± 9.4
R 0.346 -0.202 -0.552 -0.767
P 0.004 0.098 < 0.001 < 0.001
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TFPI-2 could regulate tumor angiogenesis by reducing
synthesis of the VEGF receptor [30]. There is growing
evidence suggesting that TFPI-2 is critically involved in
the progression of angiogenesis [12,31]. We also found
that the VEGF expression and MVD in the TFPI-2 posi-
tive samples was significantly lower compared to TFPI-2
negative samples. Such result indicated that Human
TFPI-2 may inhibit VEGF-stimulated capacity of angio-
genesis in the development of cervical cancer, which
leads to unlimited the growth of tumors.
The Ki67 antigen is a nuclear nonhistone protein to
be expressed throughout the cell cycle, except G0. In
the present study, we used Ki-67 immunohistochemistry
to determine the cell proliferative activity. We observed
that there was no signiﬁcant correlation between PI and
TFPI-2 expression in invasive cervical cancer. Our find-
ings contrast with previous studies in vitro, which
demonstrated that ectopic expression of TFPI-2 signifi-
cantly inhibited cell proliferation in hepatocellular carci-
noma [11], nasopharyngeal carcinoma [10] cell lines and
Human retinal endothelial cells [32]. These differences
may be due to variation in cell type-specific responses,
or the detection of an extensive cell cycle phase by Ki-
67 immunohistochemistry, and/or our ability to examine
complex in lesions. And further study will be essential
for discovering more valuable information about TFPI-2
expression and cell proliferation in cervical carcinoma.
Conclusions
In conclusion, our data shows the expression of TFPI-2
in cervical lesions has a decreasing trend with tumor
p r o g r e s s i o n .I ti sb e l i e v e dt h a tT F P I - 2c o n t r i b u t e st o
tumor cell apoptosis and angiogenesis in patients with
cervical cancer. TFPI-2 may be considered as a tumor
suppressor gene during the development of cervical can-
cer. As a result, we propose that TFPI-2 silencing was
probably one of the mechanisms of cervical cancer.
Future studies focused on the molecular mechanism
whereby TFPI-2 expression and function affects tumor
cell gene expression of cervical cancer are needed.
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